Epidemiologic and basic evidence for inflammation in cardiovascular disease
Inflammation plays a pivotal role in the development and progression of atherosclerosis. 1 Both innate and acquired immunity play key roles in inflammatory cell adhesion and transmigration across the endothelium, fatty streak formation, smooth muscle migration, plaque progression, and ultimately lesion rupture and thrombosis. The clinical consequences of this process include myocardial infarction (MI), stroke, and cardiovascular death.
Numerous epidemiologic studies support a key role for measures of subclinical vascular inflammation in the identification of patients at increased risk for MI and stroke. [2] [3] [4] In a comprehensive meta-analysis of N50 prospective studies, the magnitude of risk associated with a 1 SD elevation in high-sensitivity C-reactive protein (hsCRP) (a measure of subclinical vascular inflammation) was similar to that observed for a 1 SD elevation in blood pressure or total cholesterol. 5 The addition of hsCRP to traditional risk factors improves cardiovascular risk stratification 6, 7 and has led to its incorporation into cardiovascular risk prediction models and primary prevention screening guidelines. 
Clinical evidence that treating inflammation matters
To date, no clinical trial has directly addressed whether targeting inflammation alone will reduce cardiovascular risk. A number of clinical trials in both primary and secondary prevention, however, indicate that such an approach may be promising.
As first noted in the CARE trial more than a decade ago, the benefits of pravastatin were particularly pronounced among patients with evidence of ongoing vascular inflammation. 9 The AFCAPS/TexCAPS trial of lovastatin yielded similar results. 10 The JUPITER trial tested the hypothesis that markers of inflammation can identify a group of patients who do not qualify for statin therapy because of normal lipid levels but who might nonetheless benefit from treatment. JUPITER compared rosuvastatin with placebo among 17,802 individuals without preexisting cardiovascular disease or diabetes and a baseline low-density lipoprotein cholesterol (LDL-C) b130 mg/dL, but with evidence of ongoing subclinical inflammation, as determined by an hsCRP ≥2.0 mg/L at baseline. Participants randomized to active rosuvastatin had a 44% lower risk of the primary end point, a composite of cardiovascular death, nonfatal MI, nonfatal stroke, hospitalization for unstable angina, or arterial revascularization. 11 Further analyses indicated that the reduction in cardiovascular events derived from both the observed reduction in vascular inflammation, as measured by hsCRP, and from reductions in LDL-C. 12 In secondary prevention populations, hsCRP also has a strong relationship with recurrent events. Achieved levels of hsCRP and LDL-C independently relate to the risk of recurrent events in a number of randomized trials of patients post acute coronary syndrome, including the PROVE IT-TIMI 22 and A to Z studies of usual versus intensive statin therapy. 13, 14 When viewed together with JUPITER, data from these 3 trials, conducted in either primary or secondary prevention, support the concept of using a dual target strategy of LDL-C and hsCRP reduction for cardiovascular disease prevention. As statins substantially lower both inflammation (as gauged by hsCRP) and LDL-C, none of these trials tested whether lowering inflammation alone-without lowering LDL-C-would lower vascular risk. CIRT's primary aim tests this hypothesis, a matter of considerable clinical therapeutic as well as mechanistic biological interest (ClinicalTrials. gov NCT01594333).
Type 2 diabetes, metabolic syndrome, and inflammation
Approximately 30% to 40% of patients with acute coronary syndromes have diabetes or metabolic syndrome, many diagnosed with these dysmetabolic states the time of their presentation. 15, 16 Post-MI patients with type 2 diabetes or the metabolic syndrome have an increased risk of recurrent cardiovascular events, including MI, stroke, and cardiovascular death. In the MIRACL, WIZARD, and TNT trials, patients with metabolic syndrome had a 33% to 44% increased risk of recurrent cardiovascular events. [17] [18] [19] Patients with diabetes were also at markedly elevated risk, with nearly double the event rate of those without diabetes in CARE (19.1% vs 10.5%), 20 and had an adjusted relative risk that ranged from 1.4 (95% CI 1.3-1.5) in LIPID to 1.62 (1.29-2.03) in 4S. 21, 22 Preventing macrovascular events in patients with diabetes and the metabolic syndrome remains challenging, and many recent trials of intensive lipid, 23 blood pressure, 24 glucose lowering, 25, 26 or early coronary revascularization 27 have failed to show reductions in cardiovascular events and mortality. Therefore, novel approaches to preventing the macrovascular complications of insulin resistance and diabetes are urgently needed. Patients with type 2 diabetes or the metabolic syndrome also have a high prevalence of subclinical vascular inflammation, as determined by high levels of circulating inflammatory biomarkers. 28, 29 Indeed, some investigators have hypothesized that alterations in innate immunity underlie insulin resistance and diabetes. 30 Methotrexate and cardiovascular disease: epidemiology and molecular mechanisms Directly testing the inflammatory hypothesis of atherothrombosis requires an agent that has systemic antiinflammatory effects without substantive impact on lipids or blood pressure. The agent must also be well tolerated and have a reasonable safety profile. Low-dose methotrexate (LDM) has these characteristics.
Low-dose methotrexate (dose range 10-30 mg/wk) is widely used as first-line treatment for patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis. Because of the wide use of LDM as primary therapy for several rheumatologic conditions, the American College of Rheumatology has published safety guidelines regarding dosing regimens, drug monitoring, and the identification of high-risk patient subgroups. 31, 32 Lowdose methotrexate reduces several inflammatory biomarkers including C-reactive protein, interleukin 6, and tumor necrosis factor α in patients with rheumatologic disease, without affecting lipid levels, blood pressure, platelet function, or measures of hemostasis. 33 Moreover, among patients with rheumatoid arthritis and psoriasis, epidemiologic data suggest that LDM reduces cardiovascular risk, although patients taking LDM tended to have higher vascular risk profiles. Indeed, a recent meta-analysis found that patients with rheumatologic disease on methotrexate had a 21% lower risk of cardiovascular events (relative risk 0.79, 95% CI 0.73-0.87, P b .001) compared with those on other disease-modifying antirheumatic therapy. 34 Methotrexate is a dihydrofolate reductase inhibitor. When given at high doses, it prevents the synthesis of both purine and pyrimidine nucleotides. This mechanism of action forms the basis for its use in treating malignancy. However, at the far lower doses routinely used to treat rheumatoid arthritis and psoriasis, folic acid supplementation reduces methotrexate side effects without diminishing its efficacy. 35 This observation raises the possibility that methotrexate's antimetabolite properties are not responsible for its clinical benefit in these conditions, and alternative explanations for its antiinflammatory effects have emerged. For example, LDM may reduce inflammation by inhibiting the production of cytokines known to be important in atherothrombosis, including interleukin 1β, interleukin 1 receptor antagonist, interleukin 6, and tumor necrosis factor α.
36,37
Alternatively, LDM may function by inducing inflammatory cell apoptosis, perhaps through the generation of reactive oxygen species. 38 Although lymphocytes display both of these mechanisms, monocyte macrophages, the predominant inflammatory cell type in atherosclerotic plaques, do not. 37, 38 Emerging evidence raises the hypothesis that at least part of the anti-inflammatory and atheroprotective effects of LDM may result from increased adenosine release and subsequent agonism of the adenosine A 2A receptor. Stimulation of this receptor induces the expression of key proteins in reverse cholesterol transport, including 27-hydroxylase and adenosine 5′-triphosphate-binding cassette transporter A1, and prevents the formation of foam cells from human macrophages. 39, 40 A 2A stimulation also attenuates inflammation and neointima formation after arterial injury in mice and reduces expression of adhesion molecules commonly associated with the development of atheroma, such as vascular cell adhesion molecule-1 and intercellular adhesion molecule-1. 41 Direct anti-inflammatory effects at the level of the vascular endothelium also likely have relevance; in New Zealand rabbits consuming a high-cholesterol diet, weekly intravenous methotrexate administration reduced new atheroma formation by 75% and led to a 2-fold reduction in the intima-to-media ratio and a marked reduction of macrophages and apoptotic cells within the aorta intima. 42 
CIRT: a direct test of the inflammatory hypothesis of atherothrombosis
The CIRT's primary objective is to determine whether anti-inflammatory therapy with LDM (target dose 15-20 mg/wk) as compared with placebo will reduce the rate of recurrent cardiovascular events among patients with prior MI and either type 2 diabetes or the metabolic syndrome. The primary trial end point, the composite of nonfatal MI, nonfatal stroke, and cardiovascular death, will be adjudicated by an independent Clinical Events Committee (CEC) blinded to study treatment allocation. Secondary trial end points are all-cause mortality, the primary end point plus coronary revascularization, hospitalization for congestive heart failure, the primary end point plus all-cause mortality plus coronary revascularization plus hospitalization for congestive heart failure, net clinical benefit or harm, and new onset type 2 diabetes among those with metabolic syndrome but not diabetes at study entry. Of these, events adjudicated by the CEC include all-cause mortality, all arterial revascularizations (including coronary revascularization), and hospitalization for congestive heart failure. The CEC will also adjudicate cases of unstable angina requiring unplanned revascularization. Tertiary end points are individual components of the primary end point, the primary end point plus unstable angina requiring unplanned coronary revascularization, coronary revascularization, peripheral artery disease, symptomatic deep vein thrombosis or pulmonary embolism, clinically significant aortic stenosis, atrial fibrillation, and standardized measure of quality of life and global health status. The effects of random allocation to LDM on a number of clinical events of interest thought to be related to subclinical inflammation will be assessed. These include age-related macular degeneration, 43 sleep apnea, 44 and microvascular disease (nephropathy 45, 46 and retinopathy 47 ). CIRT will randomize 7,000 participants age ≥18 years who have had a documented MI at least 60 days but no more than 5 years before screening. Eligible participants will also have either type 2 diabetes or the metabolic syndrome (defined by American Heart Association/ National Heart Lung and Blood Institute criteria) 48 , will be medically stable, will have completed all planned coronary revascularization procedures, and will provide written informed consent. The inclusion and exclusion criteria for CIRT (Table) either match or exceed those published by the American College of Rheumatology's guidelines for the use of LDM in patients with rheumatoid arthritis. 31 Patients with a contraindication to methotrexate such as a history of chronic infection, tuberculosis, interstitial pneumonitis, pulmonary fibrosis, alcohol abuse, hepatic or renal dysfunction, or class IV heart failure will be excluded, as will women of childbearing potential and those requiring treatment with oral steroids or other immunosuppressive agents. Participants will continue to take indicated secondary prevention medications, including, for example, dual antiplatelet therapy, β-blockers, statins, angiotensinconverting enzyme inhibitors or receptor blockers, and anticoagulants.
The overall study design of CIRT is shown in Figure 1 . At the initial screening visit, informed consent will be obtained from eligible participants (Table) , and blood samples for hepatitis B surface antigen and hepatitis C antibody, alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, albumin, glucose, and a complete blood count will be collected. If all laboratory values meet the prespecified criteria, enrollment will be scheduled within 12 weeks. At the enrollment visit, lipids, glycated hemoglobin, hsCRP, and urinary albumin and creatinine will be ascertained, and all participants entered into a 5-to 6-week (8-week maximum) open-label active run-in designed to exclude before randomization those initially intolerant of LDM. During this run-in, methotrexate dosing will increase from an initial weekly dose of 5 mg to the randomization target dose of 15 mg weekly. For those who clinically tolerate methotrexate during the run-in, show no signs of laboratory abnormality, and wish to continue, formal randomization will occur either to LDM or to placebo. All study drug will be dispensed in calendar packs with active LDM (or LDM placebo) to be taken once weekly on Saturday and folic acid 1 mg to be taken Sunday through Friday. Randomization will be stratified by time since qualifying MI (b6 months, ≥6 months), site, and the presence of either type 2 diabetes or the metabolic syndrome.
A member of the study staff will see participants every 4 months after randomization. Between the in-person visits, randomized participants will undergo monthly safety evaluations for the first 6 months of the trial and bimonthly safety evaluations after 6 months. Safety evaluations include an assessment of adherence, side effects, safety laboratories, and existing medical conditions or planned procedures that might alter study drug dosing. These visits also include screening for the occurrence of primary, secondary, and other clinical events of interest.
At randomization, participants will be assigned to active methotrexate 15 mg/wk or to matching placebo. For those tolerant of study drug 4 months after randomization, up-titration to the maximal allowed dose of 20 mg weekly (or to matching placebo) will occur. To ensure consistency of methotrexate management at all study sites and to preserve the study blinding, dose changes will be made centrally using a formal titration algorithm specifically designed for CIRT (Figure 2) . At a given visit or safety evaluation, the algorithm will integrate the collected information to determine whether the current study medication dose should change. The dose can be increased by 5 mg (if not already at the maximum allowed dose), maintained, decreased by 5 mg, stopped temporarily, or stopped permanently (Figure 2 ). The algorithm allows dose adjustments for hospitalizations, infections, surgical procedures, and other clinical events (including the occurrence of the primary end point) and specifies repeat evaluations for possible resumption of study drug, continuation of a temporary stop, permanent stop, and sham changes in the placebo arm of the trial. This centralized titration algorithm also incorporates a matrix of current study drug dose and thresholds for the routine safety laboratories of white blood cell count, platelets, estimated creatinine clearance, AST, ALT, and hematocrit as well as patient symptoms (Figure 3) . Thus, as is common when using LDM in the setting of rheumatoid arthritis or psoriasis, dosing for individual participants will vary over time in response to transient medical conditions. However, the weekly dose will never exceed the maximum 4-month up-titration dose of 20 mg. Liver transaminase levels (AST/ALT) greater than the upper limit of normal or albumin less than the lower limit of normal Creatinine clearance b40 mL/min as estimated by the Cockcroft-Gault equation History of alcohol abuse or unwillingness to limit alcohol consumption to b4 drinks per week Women of child bearing potential, even if currently using contraception, and women intending to breastfeed Men who plan to father children during the study period or who are unwilling to use contraception Requirement for use of drugs that alter folate metabolism (trimethoprim/ sulfamethoxazol) or reduce tubular excretion (probenecid) or known allergies to antibiotics making avoidance of trimethoprim impossible Current indication for methotrexate therapy Chronic use of oral steroid therapy or other immunosuppressive or biologic response modifiers Known chronic pericardial effusion, pleural effusion, or ascites New York Heart Association class IV congestive heart failure Life expectancy of b3 y ⁎ The most recent American Heart Association/NHLBI definition of metabolic syndrome 48 will be used and requires evidence that any 3 of the following 5 diagnostic criteria are present: waist circumference ≥102 cm in men or ≥88 cm in women; triglycerides ≥150 mg/dL (1.7 mmol/L) or on-drug treatment for elevated triglycerides (fibrates, nicotinic acid, or omega 3 fatty acids); high-density lipoprotein cholesterol b40 mg/dL in men or b50 mg/dL in women or on-drug treatment for reduced high-density lipoprotein cholesterol (fibrates or nicotinic acid); systolic blood pressure ≥130 mm Hg or diastolic blood pressure ≥85 mm Hg or on-drug treatment for hypertension; and elevated fasting glucose ≥100 mg/dL or on-drug treatment for elevated glucose.
A team of medical monitors with experience prescribing methotrexate will be available to address questions about study drug safety throughout the trial. The medical monitor will have access to individual participant laboratory results, clinical symptoms, and study drug dosage. Monitors can help sites determine whether the participant's clinical scenario merits temporary or permanent interruption of study drug therapy and whether study drug can be reintroduced.
The routine in-person and telephone visits described above will be used to monitor the occurrence of adverse events. Adverse events will be categorized as serious or nonserious and will be graded by investigators with respect to the possibility of being related to the study drug. Investigators will also be asked to determine if the event is expected or unexpected, based on what is known about the toxicities of LDM.
CIRT is an event-driven trial designed to accrue 530 total confirmed major cardiovascular events over an estimated average follow-up of 3 to 4 years. The trial has a 90% power to detect a 25% relative hazard reduction in the primary end point, based on a 2-sided log-rank test with α = .05. A formal prespecified Statistical Analysis Plan is available in the online Appendix A to this article. The formal DSMB Charter is available from the investigators.
After trial completion and cessation of study drug, an additional 3-month washout phase is incorporated into CIRT to address whether LDM results in any long-term benefits on hemoglobin A1c and other biomarkers of insulin resistance. At trial enrollment, randomization, and 8 months and 24 months after randomization, participants will be given the opportunity to donate blood and DNA samples into a biobank being established Simplified flow diagram of CIRT. Clinically stable patients with a history of MI in the past 5 years and either type 2 diabetes or the metabolic syndrome will enter a 5-to 6-week active run-in period with escalating doses of methotrexate (advancing from 5 mg/wk to 15 mg/wk). Those who tolerate the run-in and have no new laboratory abnormalities will then be randomized to active methotrexate or placebo and followed up for an average period of 3 to 5 years. The primary end point is the occurrence of myocardial recurrent infarction, stroke, or cardiovascular death. All safety evaluations except visit 2.5 consist of a safety laboratory evaluation and either a telephone or an in-person visit to ascertain medication side effects, adverse events, and any key clinical end points. Visit 2.5 is a telephone visit without laboratory assessment. M5-M10-M15-M20 indicates variable dose of active methotrexate with a target dose of 15 to 20 mg/wk. P5-P10-P15-P20 indicates variable dosing of methotrexate placebo. The maximum dose of methotrexate is 15 mg/wk until 4 months after randomization, when the dose can be increased to 20 mg/wk. Abbreviations: Eval, Evaluation; MTX, methotrexate; T2DM, type 2 diabetes mellitus; VN, visit N (a representative follow-up visit); VF, final visit.
as part of CIRT. These samples will be available after trial completion and used on a prespecified basis to address issues of effect modification by genotype and inflammatory biomarker status as well as for a series of ancillary investigations.
Trial sponsorship and organization
CIRT is funded by the National Heart Lung and Blood Institute (NHLBI) through a U01 mechanism to Dr Paul Ridker (HL101422), the trial principal investigator, and to Dr Robert J. Glynn (HL101389) who is the Director of the Data Coordinating Center. Drs Ridker and Glynn conduct all trial activities at Brigham and Women's Hospital and Harvard Medical School in Boston, MA.
TEVA, Inc, is supplying active methotrexate (Trexall 5 mg), and Amneal Pharmaceuticals, Inc, is supplying active folic acid (Folvite 1 mg) . Catalent, Inc, is supplying methotrexate placebo as well as drug packaging and distribution services. To improve compliance, safety, and drug accountability, 8-week child-resistant calendar packs are being used for all study drug allocation both during the trial run-in phase and the active treatment phase. The Investigational New Drug Application with the US Federal Drug Administration and the Clinical Trial Application with Health Canada will be held by the trial principle investigator.
CIRT is overseen by a fully independent Data and Safety Monitoring Board (DSMB), convened by the NHLBI and chaired by Robert Harrington, MD. The members of the DSMB are listed in online Appendix B Supplementary  Table I . The DSMB will report directly to the funding 
Titration Algorithm Overview
Schematic representation of the study drug titration algorithm. Flow diagram for changes in study drug dose. Using information gathered from routine questionnaires and regular safety laboratory studies, the dose of study drug can be increased, maintained, decreased, and stopped (temporarily or permanently). Sham dose changes in the placebo arm maintain the study blind.
entity (NHLBI) and will have responsibility for monitoring enrollment and adherence, biomarkers of safety, adverse events, serious adverse events, the occurrence of trial end points, and participant and site burden. The DSMB Charter prospectively establishes guidelines for possible early termination of the study (for efficacy or futility).
Current members of the CIRT Advisory Committees, including the Executive Committee, the Steering Committee, the Publications Committee, the Ancillary Study Committee, the Arthritis and Methotrexate Advisory Committee, the Clinical Endpoints Committee, the Data Coordinating Center Committee, the Operations Committee, and the NHLBI Project Officer and Staff are listed in online Appendix B Supplementary Table II. Additional information regarding CIRT can be obtained at theCIRT.org Web site, by calling the Data coordinating center at 855-437-9330 or at www.ClinTrials.gov (NCT01594333). The authors are solely responsible for the drafting and editing of this manuscript and its contents.
Conclusion
Inflammation mediates the effects of many risk factors on arterial biology and thus drives atherothrombosis. Although considerable evidence suggests that reducing inflammation leads to improved cardiovascular outcomes, no study has yet tested whether directly targeting inflammation will reduce the occurrence of heart attack, stroke, and cardiovascular death. By using LDM, an effective systemic anti-inflammatory medication without known effects on traditional determinants of cardiovascular risk, CIRT seeks to test whether directly treating inflammation can reduce the occurrence of heart attack, stroke, and cardiovascular death. If LDM reduces cardiovascular events, CIRT would both support Matrix of routine safety laboratory values and clinically important symptoms and the participant's current study drug dose. This matrix is used in the drug titration algorithm to determine the dose of study drug the participant should take after the safety evaluation.
